This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack
CJC-1295 DAC and Ipamorelin are research peptides studied for their effects on growth-hormone signaling pathways. CJC-1295 DAC is a long-acting growth hormone-releasing hormone analogue, while Ipamorelin is a selective ghrelin-receptor agonist. This entry summarizes their research classification, mechanisms under investigation, available scientific evidence, limitations, and research-material information.
Quick Reference
Storage Instructions
Proper storage preserves peptide integrity and efficacy.
• Lyophilized (dry powder): Store at ≤−15 °C (5 °F); preferably ≤−50 °C (−58 °F) for long-term storage[5].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks[6].
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Avoid repeated freeze–thaw cycles of reconstituted solutions.
How is CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack studied?
CJC-1295 DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue studied for prolonged activation of GHRH signaling. Its Drug Affinity Complex (DAC) is designed to bind circulating proteins, extending its presence compared with shorter-acting analogues [1]. Ipamorelin is a selective ghrelin-receptor (GHSR) agonist investigated for its effects on growth-hormone release [2]. In research settings, the combination is studied because the compounds act through different receptor pathways involved in growth-hormone signaling. These mechanistic findings do not establish clinical benefit or safety.
What does the research report about CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack?
Research findings reported in the cited literature include changes in growth-hormone and IGF-1 signaling and body-composition outcomes studied with GH secretagogues [7]. CJC-1295 DAC has been reported to produce prolonged GH/IGF-1 elevations in human research [1], while Ipamorelin has been investigated for selective growth-hormone release with limited effects on cortisol and ACTH in the cited research [2]. Tolerability findings and reported adverse events should be interpreted within the specific study populations and designs [8]. These findings do not establish the safety, efficacy, or expected effects of the CJC-1295 DAC + Ipamorelin combination for personal use.
Research Limitations / Risk Notes
Evidence for CJC-1295 DAC and Ipamorelin should be interpreted according to the design and population of each individual study. Findings reported for either compound alone should not automatically be applied to the combined stack. Preclinical, animal, early-stage, and human findings should be distinguished clearly, and the available research does not establish the safety, efficacy, or clinical benefit of this combination for personal use.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.